Abstract:Brain metastases (BM), with a dismal prognosis, are a common and lethal complication of non-small cell lung cancer. Approximately, 10% patients present with BM at their initial diagnosis. Although, surgery and/or radiation therapy remain to be the mainstay treatment, targeted therapies are finding increasing application in treating BM. However, due to the very limited accessibility of brain lesions, its genomic and epigenomic landscape remain elusive. Capture-based targeted sequencing for somatic mutation profiling was performed on 27 treatment-naïve advanced NSCLC patients with paired lung primary and BM lesions using a pane consisting of 520 cancer related genes. DNA methylation analyses was performed on same samples using a DNA methylation panel consisting of 100,000 CpG sites. Collectively, we identified 370 (291 SNVs+Indels, 78 CNVs and 1 rearrangement) and 574 (245 SNVs+Indels, 327 CNVs and 2 rearrangements) mutations from lung primary lesions and BM, respectively. Among them, 242 mutations were shared; 128 were lung primary-specific and 332 were BM-specific. Among the BM specific mutations, a majority of them (82%, 272/332) were copy number variations (CNVs). Only 16% of CNVs were shared by lung lesions and BM. The concordance for SNVs and indels were much higher-54% between the two sources of tissues. Furthermore, we observed a much higher concordance rate (79%) in TP53 and classic lung cancer driver genes than other genes (p<0.001), indicating that they might be stem mutations. Next, we performed pathway analysis of genes that were only mutated in BM and revealed an enrichment of genes participating in PI3K-AKT and focal adhesion pathways. We also compared tumor mutation burden (TMB) between them and revealed comparable TMB (p=0.1). Our DNA methylation analysis revealed distinct methylation patterns with 268 blocks that are significantly differentially methylated between primary lung lesions and BM. Among them, 211 blocks were hypermethylated in BM and the remaining 57 blocks were hypermethylated in lung lesions. These blocks were enrichment in genes participating in cell adhesion, Rap1 signaling and calcium signaling pathways. We revealed diverse somatic mutation and DNA methylation profiles between lung primary lesions and BM. BM had significantly more unique CNVs. A great concordance was observed for classic lung cancer driver genes and TP53. Our study provided a comprehensive view of genomic and DNA methylation profiling for lung primary lesions and BM, paving the avenue for the development of targeted therapies for treating BM.

Significance of Methylation of FBP1 Gene in Non-Small Cell Lung Cancer

P1.01-18 Integrated Genomic and DNA Methylation Analyses of Non-Small Cell Lung Cancer Patients with Brain Metastases

A Novel DNA Methylation Signature Revealed GDF6 and RCC1 As Potential Prognostic Biomarkers Correlated with Cell Proliferation in Clear Cell Renal Cell Carcinoma

Down-regulation of FBP1 in Lung Adenocarcinoma Cells Promotes Proliferation and Invasion Through SLUG Mediated Epithelial Mesenchymal Transformation

Transcriptional Inactivation of Secreted Frizzled-Related Protein 1 by Promoter Hypermethylation As a Potential Biomarker for Non-Small Cell Lung Cancer.

Promoter Hypermethylation Mediated Downregulation Of Fbp1 In Human Hepatocellular Carcinoma And Colon Cancer

HIF1A-dependent Overexpression of MTFP1 Promotes Lung Squamous Cell Carcinoma Development by Activating the Glycolysis Pathway

Aberrant Promoter Methylation of FBLN-3 Gene and Clinicopathological Significance in Non-Small Cell Lung Carcinoma.

FBP1 inhibits NSCLC stemness by promoting ubiquitination of Notch1 intracellular domain and accelerating degradation

Infrequently methylated event at sites −362 to −142 in the promoter of TGFβR1 gene in non-small cell lung cancer

Analysis of Methylation Status of RASSF1A promoter Region and Transcription Level of Downstream Genes in Non-Small Cell Lung Cancer

FOXP family DNA methylation correlates with immune infiltration and prognostic value in NSCLC

Quantitative Assessment of Gene Promoter Methylation in Non-Small Cell Lung Cancer Using Methylation-Sensitive High-Resolution Melting.

Infrequently Methylated Event At Sites-362 To-142 In The Promoter Of Tgf Beta R1 Gene In Non-Small Cell Lung Cancer

DNMT3A-mediated DNA methylation and transcription inhibition of FZD5 suppresses lung carcinogenesis

Fructose-1,6-bisphosphatase 1 suppresses PPARα-mediated gene transcription and non-small-cell lung cancer progression.

Abnormal hypermethylation and clinicopathological significance of FBLN1 gene in cutaneous melanoma

Methylation of Promoter for Hmlh1 in Non-small Cell Lung Cancer

Overexpression of FBP1 Enhances Dendritic Cell Activation and Maturation by Inhibiting Glycolysis and Promoting the Secretion of IL33 in Lung Adenocarcinoma

Identification Of Epigenetic Aberrant Promoter Methylation Of Rassf1a In Serum Dna And Its Clinicopathological Significance In Lung Cancer

Identification and Validation of the Methylation Biomarkers of Non-Small Cell Lung Cancer (NSCLC).